Marjan Wouthuyzen-Bakker1, Joris J W Ploegmakers2, Karsten Ottink2, Greetje A Kampinga1, Lucie Wagenmakers-Huizenga3, Paul C Jutte2, Anneke C M Kobold3. 1. Department of Medical Microbiology and Infection Prevention, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 2. Department of Orthopaedic Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 3. Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Abstract
BACKGROUND: To diagnose or exclude a chronic prosthetic joint infection (PJI) can be a clinical challenge. Therefore, sensitive and specific biomarkers are needed in the diagnostic work-up. Calprotectin is a protein with antimicrobial properties and is released by activated neutrophils, making it a specific marker for infection. Because of its low costs and ability to obtain a quantitative value as a point of care test, it is an attractive marker to use in clinical practice. In addition, the test is already used in routine care in most hospitals for other indications and therefore easy to implement. METHODS: Between June 2015 and June 2017 we collected synovial fluid of all consecutive patients who underwent revision surgery of a prosthetic joint because of chronic pain with or without prosthetic loosening. Synovial calprotectin was measured using a lateral flow immunoassay. A PJI was defined by the diagnostic criteria described by the Musculoskeletal Infection Society. RESULTS: Fifty-two patients with chronic pain were included. A PJI was diagnosed in 15 of 52 (29%) patients. The median calprotectin in the PJI group was 859 mg/L (interquartile range 86-1707) vs 7 mg/L (interquartile range 3-25) in the control group (P < .001). With a cut-off value of 50 mg/L, synovial calprotectin showed a sensitivity, specificity, positive predictive value, and negative predictive value of 86.7%, 91.7%, 81.3%, and 94.4%, respectively. CONCLUSION: Synovial calprotectin is a useful and cheap biomarker to use in the diagnostic work-up of patients with chronic pain, especially to exclude a PJI prior to revision surgery.
BACKGROUND: To diagnose or exclude a chronic prosthetic joint infection (PJI) can be a clinical challenge. Therefore, sensitive and specific biomarkers are needed in the diagnostic work-up. Calprotectin is a protein with antimicrobial properties and is released by activated neutrophils, making it a specific marker for infection. Because of its low costs and ability to obtain a quantitative value as a point of care test, it is an attractive marker to use in clinical practice. In addition, the test is already used in routine care in most hospitals for other indications and therefore easy to implement. METHODS: Between June 2015 and June 2017 we collected synovial fluid of all consecutive patients who underwent revision surgery of a prosthetic joint because of chronic pain with or without prosthetic loosening. Synovial calprotectin was measured using a lateral flow immunoassay. A PJI was defined by the diagnostic criteria described by the Musculoskeletal Infection Society. RESULTS: Fifty-two patients with chronic pain were included. A PJI was diagnosed in 15 of 52 (29%) patients. The median calprotectin in the PJI group was 859 mg/L (interquartile range 86-1707) vs 7 mg/L (interquartile range 3-25) in the control group (P < .001). With a cut-off value of 50 mg/L, synovial calprotectin showed a sensitivity, specificity, positive predictive value, and negative predictive value of 86.7%, 91.7%, 81.3%, and 94.4%, respectively. CONCLUSION: Synovial calprotectin is a useful and cheap biomarker to use in the diagnostic work-up of patients with chronic pain, especially to exclude a PJI prior to revision surgery.
Authors: Martin McNally; Ricardo Sousa; Marjan Wouthuyzen-Bakker; Antonia F Chen; Alex Soriano; H Charles Vogely; Martin Clauss; Carlos A Higuera; Rihard Trebše Journal: Bone Joint J Date: 2021-01 Impact factor: 5.082
Authors: Alexander J Trotter; Rachael Dean; Celia E Whitehouse; Jarle Mikalsen; Claire Hill; Roxanne Brunton-Sim; Gemma L Kay; Majeed Shakokani; Alexander Z E Durst; John Wain; Iain McNamara; Justin O'Grady Journal: Bone Joint Res Date: 2020-06-08 Impact factor: 5.853
Authors: Jodie L Morris; Hayley L Letson; Andrea Grant; Matthew Wilkinson; Kaushik Hazratwala; Peter McEwen Journal: Biol Open Date: 2019-09-18 Impact factor: 2.422
Authors: Karsten D Ottink; Stefan J Gelderman; Marjan Wouthuyzen-Bakker; Joris J W Ploegmakers; Andor W J M Glaudemans; Paul C Jutte Journal: J Bone Jt Infect Date: 2022-01-06